The brand, operated by the Innocan Pharma Corporation subsidiary B.I. Sky Global Ltd., has leveraged e-commerce dominance to scale its reach. According to Roni Kamhi, CEO of B.I. Sky Global, the growth validates a business model centered on precise product development and targeted digital marketing efforts. For the parent company, Innocan, this consumer-facing success complements its broader pharmaceutical portfolio, which includes the development of CBD-loaded liposome drug delivery platforms for pain management.

Iris Bincovich, CEO of Innocan Pharma, noted that the milestone reflects both product quality and the team's ability to anticipate changing consumer preferences. Beyond the immediate sales figures, the company views this momentum as a key indicator of sustainable long-term value for shareholders as it continues to balance its interests in the wellness and pharmaceutical sectors.